Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer
Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 1
Abstract
Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is lacking. Materials and methods: This was a longitudinal, retrospective cohort study of patients with stage IIIB/IV non-squamous NSCLC aged 21 years or greater diagnosed between 2005 and 2010 at four Cancer Research Network sites. Patients were categorized as receiving first-line carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) within 120 days of diagnosis. Information on patient and tumor characteristics was obtained from queries of sites’ electronic tumor registries and administrative databases. Factors independently associated with CPB use were evaluated using bivariate and multivariate logistic regression analyses. Results: A total of 1109 patients with advanced NSCLC were included with 198 (17.9%) and 911 (82.1%) patients receiving CPB and CP, respectively. Bevacizumab use increased modestly during the study period, peaking in 2008 at 18.5%. In bivariate analyses, patients who received CPB were younger with less comorbidity and well to moderately differentiated tumors while patients who received CP were more likely to have had hypertension, peripheral vascular disease, and a prior hospitalization. Factors independently associated with CPB use included younger age, well/moderately differentiated tumor grade, no prior hospitalization, and more recent study year. Conclusions: Use of bevacizumab in patients with advanced NSCLC increased rapidly then moderated. Younger patients and those with lower risks for adverse effects were more likely to receive bevacizumab.
Authors and Affiliations
Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Bowles EJA, Menter A, Loggers ET, Ritzwoller D
Keywords
Related Articles
- EP ID EP547272
- DOI 10.14312/2052-4994.2014-1
- Views 73
- Downloads 0
Apocrine carcinoma of the scalp – A case report and highlights for diagnosis
Apocrine sweat gland carcinoma is a rare cutaneous adnexal neoplasm that may occur in the scalp, eyelid, and ear canal. More often, it presents as an asymptomatic, slow-growing, solid or cystic mass with variable color....
Contributions of stochastic events to biological evolution and cancer
Stochastic genetic and epigenetic events have been fundamental in contributing to the development of manifold life-forms, past and present. The development of malignant cell clones and the role of stochasticity as a driv...
Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis
We have developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate, part of a method we call “KORTUC II”. This study aimed to evaluate the safety and effectiveness of KORTUC II specifically for p...
Comparing docetaxel with gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study
Background: Platinum-based doublet chemotherapy is the backbone of treatment in advanced non-small cell lung cancer (NSCLC) however second-line treatment options are controversial particularly in patients with borderline...
The prevention and treatment of peritoneal carcinomatosis from gastric cancer: A 2013 update
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in...